Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2001

View Archived Issues

Antitumor activity of new VEGFR2 inhibitor under study at Boehringer Ingelheim

Gilead achieves several key R&D milestones during Q3

Elan highlights Q3 developments

TAP prodrug of duocarmycin derivative shows increased tumor specificity

Rapid anthrax test will be available to U.S. laboratories next week

Alexion acquires rights to immune system targets

FDA issues nonapprovable letter for IntraDose

Early NDA submission planned for Cellegy's testosterone gel

FDA grants orphan drug status for Thymitaq in treatment of HCC

NeoOncoRx to develop and market elsamitrucin

Antiallergic effects of AZG-1743, a new diphenylmethyl piperazine derivative

Pirfenidone may be useful in asthma Rx according to data presented at recent Japanese meeting

Chest 2001: cilomilast reduces sputum neutrophil count in COPD patients

Clinical course of malignant pleural effusions in NSCLC not changed by rhuMAb-VEGF

Adenosine modulation by pentostatin shows beneficial effects in septic mice

Further subgroup analyses of PROWESS data presented at Chest 2001

TNFerade gene therapy + radiation safely shrinks tumors in phase I trial

Phase III trials of RSR-13 in NSCLC under consideration at Allos based on phase II survival data

New analgesic from Vita enters clinical trials

Cancer-related protease inhibitor from Wilex reduces tumor growth and spread at nontoxic doses

Novel compounds from Knoll inhibit monoamine reuptake, bind to 5-HT1A receptors

Recent patent covers BMS's new DPP-IV inhibitors

Carbamic acid-based IP receptor antagonists reportedly useful for bladder disorders, etc.

Aventis prepares beta-carboline inhibitor of IKK which prolongs cardiac graft survival

New series for obesity and sleep disorders disclosed by Actelion

Selective COX-2 inhibitors synthesized by Almirall Prodesfarma

Novel compounds described in recent patent as chemokine IL-8 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...